Tel Aviv Sourasky Medical Center has entered into an agreement to expand on an existing collaboration and lease three state-of-the-art cleanrooms with an Israeli adult stem cell therapy manufacturer, enabling the company to significantly increase their capacity to manufacture and ship its product into the European Union and local Israeli market. The cleanroom facility, part of Sourasky’s Institute for Advanced Cellular Therapies, is sought after by BrainStorm Cell Therapeutics (NASDAQ: BCLI) to produce their NurOwn® (autologous MSC-NTF), a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. The underlying advanced regenerative technology was invented right there at Tel Aviv University.
TrialSite News updates the audience with a summary of this agreement.
Is this a way for Tel Aviv Sourasky Medical Center (“Sourasky”) to monetize its facility, know-how and talent in the important nascent cell and gene therapy product market.
Yes. Although the terms haven’t been disclosed, they could very well be substantial.
Does Sourasky, especially through its “Institute for Advanced Cellular Therapies,” have exp...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).